Clinical trial · Interventional
Short-term Effects of Preoperative Exercise in Moderate-to-high Perioperative Risk Lung Cancer Patients
Short-term Effects of Preoperative Exercise in Moderate-to-high Perioperative Risk Lung Cancer Patients(PRE-EXELUCA): a Prospective Randomized Controlled Clinical Trial
NCT06215326CI-TRIAL-00120339PRE-EXELUCArecruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this clinical trail is to compare the effects of preoperative exercise training of different intensities on short-term cardiorespiratory function and postoperative outcomes in patients scheduled for lung resections.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| high-intensity interval training | Behavioral | — | UNRESOLVED |
| moderate-intensity continuous training | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Moderate-intensity Continuous Training (MICT) Group
- description
- MICT plan is containing usual care protocol and additional complete a total of 12 supervised moderate-intensity continuous training sessions in 2 weeks.
- interventionNames
- Behavioral: moderate-intensity continuous training
- type
- EXPERIMENTAL
- label
- High-intensity Interval Training (HIIT) Group
- description
- HIIT plan is containing usual care protocol and additional complete a total of 12 supervised high-intensity interval training training sessions in 2 weeks.
- interventionNames
- Behavioral: high-intensity interval training
- type
- NO_INTERVENTION
- label
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age\>18 years. 2. Suspected or confirmed primary lung cancer with scheduled surgical treatment. 3. Moderate-to-high perioperative risk, defined as FEV1\<60% of predicted value (wedge) or ppo FEV1\<60% of predicted value (lobectomy/segmentectomy) or VO2peak\<20 ml/kg/ min. 4. Sign informed consent and accept to comply with the requirements of the study protocol. 5. Completion of a baseline Complete cardiopulmonary exercise testing (CPET). Exclusion Criteria: 1. Concurrent or previous history of other malignant tumors. 2. Life expectancy less than 1 year. 3. Dementia; infirmity; or inability to participate in sports (musculoskeletal limitations, namely, injuries, frailty, and weakness). 4. Inability to maintain exercise training. 5. Irregular vital signs (heart rate: \< 40 or \> 120 bpm at rest; blood pressure: systolic blood pressure \> 200 mm Hg or diastolic pressure \> 110 mm Hg; T: ≥ 38.5 or ≤ 36◦C; SpO2 ≤ 90%). 6. Currently enrolling in any other clinical trials. 7. Patient refusal.
References
Publications (18)
- BACKGROUNDDrevet G, Belaroussi Y, Duruisseaux M, Chalabreysse L, Grima R, Maury JM, Tronc F. Futile lobectomies following video-thoracoscopic exploration for indeterminate pulmonary nodules: a retrospective study. J Thorac Dis. 2022 Aug;14(8):2826-2834. doi: 10.21037/jtd-21-1789. PMID 36071782
- RESULTSung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4. PMID 33538338
- RESULTXia C, Dong X, Li H, Cao M, Sun D, He S, Yang F, Yan X, Zhang S, Li N, Chen W. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl). 2022 Feb 9;135(5):584-590. doi: 10.1097/CM9.0000000000002108. PMID 35143424
- RESULTHowington JA, Blum MG, Chang AC, Balekian AA, Murthy SC. Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013 May;143(5 Suppl):e278S-e313S. doi: 10.1378/chest.12-2359. PMID 23649443
- RESULTBrunelli A, Refai MA, Salati M, Sabbatini A, Morgan-Hughes NJ, Rocco G. Carbon monoxide lung diffusion capacity improves risk stratification in patients without airflow limitation: evidence for systematic measurement before lung resection. Eur J Cardiothorac Surg. 2006 Apr;29(4):567-70. doi: 10.1016/j.ejcts.2006.01.014. Epub 2006 Feb 14. PMID 16481190
- RESULTBrunelli A, Charloux A, Bolliger CT, Rocco G, Sculier JP, Varela G, Licker M, Ferguson MK, Faivre-Finn C, Huber RM, Clini EM, Win T, De Ruysscher D, Goldman L; European Respiratory Society and European Society of Thoracic Surgeons joint task force on fitness for radical therapy. ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy). Eur Respir J. 2009 Jul;34(1):17-41. doi: 10.1183/09031936.00184308.